Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees.
Open Access
- 1 November 1994
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 180 (5) , 1985-1988
- https://doi.org/10.1084/jem.180.5.1985
Abstract
Interleukin 10 (IL-10) has been shown to inhibit endotoxin-induced tumor necrosis factor (TNF) production. To assess the role of TNF in the induction of IL-10 in endotoxemia, four healthy men were studied after a bolus intravenous injection of recombinant human TNF (50 micrograms/m2). In addition, 13 healthy chimpanzees were investigated after a bolus intravenous injection of Escherichia coli endotoxin (4 ng/kg), 6 animals received endotoxin only, 4 animals received a simultaneous intravenous injection of a monoclonal anti-TNF antibody, whereas 3 chimpanzees were treated with an anti-TNF F(ab9)2 fragment 30 min after the administration of endotoxin. TNF induced a modest rise in IL-10 concentrations peaking after 45 min (47 +/- 32 pg/ml; p < 0.05). IL-10 peaked 2 h after injection of endotoxin (202 +/- 61 pg/ml; p < 0.005). In both anti-TNF-treated groups, the early endotoxin-induced TNF activity was completely neutralized. Simultaneous anti-TNF treatment attenuated endotoxin-induced IL-10 release (73 +/- 13 pg/ml; p < 0.01 versus endotoxin alone), whereas postponed anti-TNF treatment did not significantly affect this response (p = 0.21). These results indicate that TNF, in part, mediates the induction of IL-10 in endotoxemia, resulting in an autoregulatory feedback loop.Keywords
This publication has 20 references indexed in Scilit:
- Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemiaEuropean Journal of Immunology, 1994
- Interleukin-10 production during septicaemiaThe Lancet, 1994
- Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees.1994
- Activation of Coagulation after Administration of Tumor Necrosis Factor to Normal SubjectsNew England Journal of Medicine, 1990
- Tumor necrosis factor in the pathophysiology of infection and sepsisClinical Immunology and Immunopathology, 1990
- Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.The Journal of Experimental Medicine, 1989
- ENDOTOXIN-INDUCED CYTOKINE GENE-EXPRESSION INVIVO .1. EXPRESSION OF TUMOR NECROSIS FACTOR MESSENGER-RNA IN VISCERAL ORGANS UNDER PHYSIOLOGIC CONDITIONS AND DURING ENDOTOXEMIA1989
- Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious PurpuraNew England Journal of Medicine, 1988
- ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASEThe Lancet, 1987
- Shock and Tissue Injury Induced by Recombinant Human CachectinScience, 1986